Assessing residual cardiovascular risk and vulnerable plaques via non-traditional lipids: From biomarkers to novel targets for precision therapy

Figure 1 Diagram of the residual cardiovascular risk model. Although high-intensity statin therapy can significantly reduce risk, a considerable residual cardiovascular risk persists even after achieving the target level of low-density lipoprotein cholesterol, potentially attributable to factors such as lipoprotein(a) and remnant cholesterol. Lp(a): Lipoprotein(a); RC: Remnant cholesterol; HDL-C: High-density lipoprotein cholesterol; sdLDL-C: Small dense low-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; ASCVD: Atherosclerotic cardiovascular disease.